Perera Binura, Wu Yuao, Nguyen Nam-Trung, Ta Hang Thu
School of Environment and Science, Griffith University, Nathan, Queensland, 4111, Australia.
Queensland Micro-Nanotechnology Centre, Griffith University, Nathan, Queensland, 4111, Australia.
Mater Today Bio. 2023 Aug 7;22:100767. doi: 10.1016/j.mtbio.2023.100767. eCollection 2023 Oct.
Atherosclerosis is the build-up of fatty deposits in the arteries, which is the main underlying cause of cardiovascular diseases and the leading cause of global morbidity and mortality. Current pharmaceutical treatment options are unable to effectively treat the plaque in the later stages of the disease. Instead, they are aimed at resolving the risk factors. Nanomaterials and nanoparticle-mediated therapies have become increasingly popular for the treatment of atherosclerosis due to their targeted and controlled release of therapeutics. In this review, we discuss different types of therapeutics used to treat this disease and focus on the different nanomaterial strategies employed for the delivery of these drugs, enabling the effective and efficient resolution of the atherosclerotic plaque. The ideal nanomaterial strategy for each drug type (e.g. statins, nucleic acids, small molecule drugs, peptides) will be comprehensively discussed.
动脉粥样硬化是动脉中脂肪沉积物的堆积，它是心血管疾病的主要潜在原因，也是全球发病和死亡的主要原因。目前的药物治疗方案无法有效治疗疾病后期的斑块。相反，它们旨在解决危险因素。由于纳米材料和纳米颗粒介导的疗法具有靶向和可控的治疗药物释放特性，因此在动脉粥样硬化治疗中越来越受欢迎。在这篇综述中，我们讨论了用于治疗这种疾病的不同类型的治疗方法，并重点关注用于递送这些药物的不同纳米材料策略，从而能够有效且高效地消除动脉粥样硬化斑块。我们将全面讨论每种药物类型（如他汀类药物、核酸、小分子药物、肽）的理想纳米材料策略。
